Clovis Oncology logo
Clovis Oncology CLVS

Quarterly report 2022-Q3
added 05-16-2026

report update icon

Clovis Oncology Cash Flow 2011-2026 | CLVS

Annual Cash Flow Clovis Oncology

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Operating Cash Flow

-196 M -253 M -324 M -366 M -261 M -267 M -253 M - - -65.4 M -39.8 M -34 M -

Depreciation & Amortization

8.5 M 8.2 M 7.77 M 4.6 M 2.5 M 1.14 M 761 K 444 K 250 K 353 K 185 K 83 K -

Accounts Payables

27.3 M 26.7 M 32.2 M 28.5 M 15.1 M 10.9 M 11.3 M 2.92 M 4.42 M 2.3 M 3.04 M - -

Accounts Receivables

26.9 M 26.5 M 20.6 M 12.9 M 6.18 M 121 K 3.24 M 1.99 M - - - - -

Total Inventories

13.7 M 30.7 M 26.5 M 27.1 M 27.5 M - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow Clovis Oncology

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- -134 M -93.6 M -58.5 M - -155 M -109 M -61.9 M - -197 M -142 M -82.5 M - -253 M -196 M -98.5 M - -283 M -211 M -101 M - -195 M -150 M -80.4 M - -212 M -152 M - - - - - - - - - - - - -14.5 M - -46.8 M -32.4 M -18.6 M - -27.2 M -17.9 M -8.19 M

Depreciation & Amortization

- 5.71 M 3.83 M 1.92 M - 6.5 M 4.48 M 2.24 M - 6.15 M 4.13 M 2.13 M - 5.73 M 3.63 M 1.72 M - 2.5 M 1.51 M 586 K - 1.91 M 1.28 M 639 K - 819 K 550 K 270 K - 548 K 949 K 467 K - 3.77 M 3.56 M 3.48 M - 185 K 123 K 62 K - 269 K 176 K 84 K - 133 K 86 K 42 K

Accounts Payables

- 18.1 M 24.2 M 22.3 M 27.3 M 23.8 M 22.5 M 20.5 M 26.7 M 35.5 M 24.3 M 36.2 M 32.2 M 31.7 M 18.5 M 43.3 M 28.5 M 30.5 M 15.9 M 13.4 M 15.1 M 14.3 M 13.4 M 23.9 M 10.9 M 11.1 M 15 M 14.1 M 11.3 M 9.32 M 5.52 M 7.37 M 2.92 M 2.43 M 2.89 M 2.8 M 4.42 M 880 K 1.59 M 3.84 M 2.3 M 2.12 M 1.4 M 2.48 M 3.04 M 3.04 M 3.04 M 3.04 M

Accounts Receivables

- 19.5 M 18.6 M 27.3 M 26.9 M 25.8 M 24.2 M 21.7 M 26.5 M 20.3 M 18.2 M 25.1 M 20.6 M 16.8 M 15.4 M 16.1 M 12.9 M 14.5 M 12.3 M 12.9 M 6.18 M 121 K 1.14 M 2.38 M 121 K 1.26 M 2.75 M 3.67 M - 3.84 M 3.94 M 2.64 M 1.99 M 1.99 M 1.99 M 1.99 M - - - - - - - - - - - -

Total Inventories

- 11.4 M 13.2 M 14.5 M 13.7 M 17.3 M 25 M 22.2 M 30.7 M 24.6 M 26.9 M 30.6 M 26.5 M 24.9 M 26.6 M 25 M 27.1 M 43.7 M 63 M 69.2 M 27.5 M 5.34 M 6.48 M 6.5 M - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Clovis Oncology, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.69 2.74 % $ 198 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 31.72 2.82 % $ 2.11 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
BioNTech SE BioNTech SE
BNTX
$ 93.62 1.49 % $ 22.6 B germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 53.82 4.33 % $ 4.84 B schweizSchweiz
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.76 3.96 % $ 258 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 0.75 9.65 % $ 34.3 M israelIsrael
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 3.13 0.16 % $ 651 M usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 31.98 2.21 % $ 861 M usaUSA
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
Forte Biosciences Forte Biosciences
FBRX
$ 21.97 0.14 % $ 284 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Galectin Therapeutics Galectin Therapeutics
GALT
$ 2.72 -2.69 % $ 174 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.02 0.06 % $ 5.45 B spainSpain
Hutchison China MediTech Limited Hutchison China MediTech Limited
HCM
$ 11.78 0.26 % $ 10.1 B chinaChina
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
- - $ 384 M britainBritain
Heron Therapeutics Heron Therapeutics
HRTX
$ 0.9 1.45 % $ 150 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 10.62 1.1 % $ 95.9 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.67 -1.48 % $ 210 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.35 -2.62 % $ 5.51 M israelIsrael